Upgrade to SI Premium - Free Trial

Stifel says Buy rated on Rhythm Pharmaceuticals (RYTM) despite EMANATE failure

March 16, 2026 6:00 PM
Stifel analyst Paul Matteis reiterated a Buy rating and $131.00 price target on Rhythm Pharmaceuticals (NASDAQ: RYTM)The analyst commented, "We ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst Comments